← BackPrestige Consumer Healthcare Inc. · DrugmakersPBH
Low riskNext report: Around Nov 5 (est.)
The short versionA profitable company with steady sales.
Going well
- Profitable, keeps 18% of sales as profit
- Brings in more cash than it spends
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 3.4% to their holdings in the quarter ending June 2026 (147 bought, 196 sold)
- Held by Ray Dalio (Bridgewater)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$48.17+0.7% that day
- Company value
- $2.3B
- Share price times all shares
- Price vs profit (P/E)
- 13.5x
- You pay about $13 for each $1 of yearly profit
- Price vs sales
- 2.1x
- Company value is 2.1 times a year of sales
- Cash vs value
- 4%
- Cash as a share of company value
- Debt vs value
- 45%
- Debt as a share of company value
From PBH's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$265.7M+6.5% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $1.1B, down 1.4% from the 12 months before. Over 5 years, sales grew about 2.9% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.10.5%
- MissDebt under half of equityNot relying on borrowed money.0.56x equity
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.17.5%
- MissProfitable every yearSteady profits, not one good year.8 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$246.4M
- PassShare count not growingNot diluting owners. Falling means buybacks.-2.3% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.54.7%
- Revenue
- $1.1B
- -4.3% vs prior year
- 5-year growth
- +2.9%/yr
- revenue, per year
- Total debt
- $1.0B
- 0.56x equity
- Current ratio
- 3.11x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $265.7M
- +6.5% YoY
- EPS
- $0.61
- vs $0.95
- Op. margin
- 19.8%
- -9.0 pts
- Gross margin
- 51.3%
- -4.9 pts
- Free cash flow
- $67.1M
- Share count
- -4.5%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 0.6
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady+3.4%Institutions added 3.4% to their holdings. 147 bought, 196 sold. 2 quarters of net buying in a row.
Shares held by institutions53.8M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-1.5%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
1.1x · $2.0B debtShares outstandingLatest reported
47MNext reportAround Nov 5 (est.)Estimated from the same quarter last year
- Results filedAug 6
- Results filedMay 13
- Results filedFeb 5
- Results filedNov 6, 2025
- Results filedAug 7, 2025
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days
No offerings, red flags or new big holders. Clean record.
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
Stock awardJohn E ByomDirector
2,981 shares
- +6% of holdings
- Now owns 54,575 shares
- Filed 1 day after trade
Stock awardCeleste A. ClarkDirector
2,981 shares
- +22% of holdings
- Now owns 16,511 shares
- Filed 1 day after trade
Stock awardJames DareccaDirector
2,981 shares
- +45% of holdings
- Now owns 9,572 shares
- Filed 1 day after trade
Stock awardJohn F. KellyDirector
2,981 shares
- +61% of holdings
- Now owns 7,832 shares
- Filed 1 day after trade
Stock awardDawn M. ZierDirector
2,981 shares
- +18% of holdings
- Now owns 19,514 shares
- Filed 1 day after trade